Impact of 'Dioxins' on Gene Expression in Mouse Liver in vivo, and in both Rat Liver Cells and Human Blood Cells In Culture

‘Dioxin-like’ (DL) compounds occur ubiquitously in the environment. Toxic responses associated with specific dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), and polychlorinated biphenyls (PCBs) include dermal toxicity, immunotoxicity, liver toxicity, carcinogenicity, as well as adverse effects on reproduction, development, and endocrine functions. Most, if not all of these effects are believed to be due to interaction of these compounds with the aryl hydrocarbon receptor (AhR). With tetrachlorodibenzo-p-dioxin (TCDD) as representatively most potent congener, a toxic equivalency factor (TEF) concept was employed, in which respective congeners were assigned to a certain TEF-value reflecting the compound’s toxicity relative to TCDD’s. The EU-project ‘SYSTEQ’ aimed to develop, validate, and implement human systemic TEFs as indicators of toxicity for DL-congeners. Hence, the identification of novel quantifiable biomarkers of exposure was a major objective of the SYSTEQ project. In order to approach to this objective, a mouse whole genome microarray analysis was applied using a set of seven individual congeners, termed the ‘core congeners’. These core congeners (TCDD, 1-PeCDD, 4-PeCDF, PCB 126, PCB 118, PCB 156, and the non dioxin-like PCB 153), which contribute to approximately 90% of toxic equivalents (TEQs) in the human food chain, were further tested in vivo as well as in vitro. The mouse whole genome microarray revealed a conserved list of differentially regulated genes and pathways associated with ‘dioxin-like’ effects. A definite data-set of in vitro studies was supposed to function as a fundament for a probable establishment of novel TEFs. Thus, CYP1A induction measured by EROD activity, which represents a sensitive and yet best known marker for dioxin-like effects, was used to estimate potency and efficacy of selected congeners. For this study, primary rat hepatocytes and the rat hepatoma cell line H4IIE were used as well as the core congeners and an additional group of compounds of comparable relevance for the environment: 1,6-HxCDD, 1,4,6-HpCDD, TCDF, 1,4-HxCDF, 1,4,6-HpCDF, PCB 77, and PCB 105. Besides, a human whole genome microarray experiment was applied in order to gain knowledge with respect to TCDD’s impact towards cells of the immune system. Hence, human primary blood mononuclear cells (PBMCs) were isolated from individuals and exposed to TCDD or to TCDD in combination with a stimulus (lipopolysaccharide (LPS), or phytohemagglutinin (PHA)). A few members of the AhR-gene batterie were found to be regulated, and minor data with respect to potential TCDD-mediated immunomodulatory effects were given. Still, obtained data in this regard was limited due to great inter-individual differences

Impact of 'Dioxins' on Gene Expression in Mouse Liver in vivo, and in both Rat Liver Cells and Human Blood Cells In Culture

‘Dioxin-like’ (DL) compounds occur ubiquitously in the environment. Toxic responses associated with specific dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), and polychlorinated biphenyls (PCBs) include dermal toxicity, immunotoxicity, liver toxicity, carcinogenicity, as well as adverse effects on reproduction, development, and endocrine functions. Most, if not all of these effects are believed to be due to interaction of these compounds with the aryl hydrocarbon receptor (AhR). With tetrachlorodibenzo-p-dioxin (TCDD) as representatively most potent congener, a toxic equivalency factor (TEF) concept was employed, in which respective congeners were assigned to a certain TEF-value reflecting the compound’s toxicity relative to TCDD’s. The EU-project ‘SYSTEQ’ aimed to develop, validate, and implement human systemic TEFs as indicators of toxicity for DL-congeners. Hence, the identification of novel quantifiable biomarkers of exposure was a major objective of the SYSTEQ project. In order to approach to this objective, a mouse whole genome microarray analysis was applied using a set of seven individual congeners, termed the ‘core congeners’. These core congeners (TCDD, 1-PeCDD, 4-PeCDF, PCB 126, PCB 118, PCB 156, and the non dioxin-like PCB 153), which contribute to approximately 90% of toxic equivalents (TEQs) in the human food chain, were further tested in vivo as well as in vitro. The mouse whole genome microarray revealed a conserved list of differentially regulated genes and pathways associated with ‘dioxin-like’ effects. A definite data-set of in vitro studies was supposed to function as a fundament for a probable establishment of novel TEFs. Thus, CYP1A induction measured by EROD activity, which represents a sensitive and yet best known marker for dioxin-like effects, was used to estimate potency and efficacy of selected congeners. For this study, primary rat hepatocytes and the rat hepatoma cell line H4IIE were used as well as the core congeners and an additional group of compounds of comparable relevance for the environment: 1,6-HxCDD, 1,4,6-HpCDD, TCDF, 1,4-HxCDF, 1,4,6-HpCDF, PCB 77, and PCB 105. Besides, a human whole genome microarray experiment was applied in order to gain knowledge with respect to TCDD’s impact towards cells of the immune system. Hence, human primary blood mononuclear cells (PBMCs) were isolated from individuals and exposed to TCDD or to TCDD in combination with a stimulus (lipopolysaccharide (LPS), or phytohemagglutinin (PHA)). A few members of the AhR-gene batterie were found to be regulated, and minor data with respect to potential TCDD-mediated immunomodulatory effects were given. Still, obtained data in this regard was limited due to great inter-individual differences

Consensus Toxicity Factors for Polychlorinated Dibenzo-p-dioxins, Dibenzofurans, and Biphenyls Combining in Silico Models and Extensive in Vitro Screening of AhR-Mediated Effects in Human and Rodent Cells

Consensus toxicity factors (CTFs) were developed as a novel approach to establish toxicity factors for risk assessment of dioxin-like compounds (DLCs). Eighteen polychlorinated dibenzo-p-dioxins, dibenzofurans (PCDD/Fs), and biphenyls (PCBs) with assigned World Health Organization toxic equivalency factors (WHO-TEFs) and two additional PCBs were screened in 17 human and rodent bioassays to assess their induction of aryl hydrocarbon receptor-related responses. For each bioassay and compound, relative effect potency values (REPs) compared to 2,3,7,8-tetrachlorodibenzo-p-dioxin were calculated and analyzed. The responses in the human and rodent cell bioassays generally differed. Most notably, the human cell models responded only weakly to PCBs, with 3,3',4,4',5-pentachlorobiphenyl (PCB126) being the only PCB that frequently evoked sufficiently strong responses in human cells to permit us to calculate REP values. Calculated REPs for PCB126 were more than 30 times lower than the WHO-TEF value for PCB126. CTFs were calculated using score and loading vectors from a principal component analysis to establish the ranking of the compounds and, by rescaling, also to provide numerical differences between the different congeners corresponding to the TEF scheme. The CTFs were based on rat and human bioassay data and indicated a significant deviation for PCBs but also for certain PCDD/Fs from the WHO-TEF values. The human CTFs for 2,3,4,7,8-pentachlorodibenzofuran, 1,2,3,4,7,8-hexachlorodibenzofuran, 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin, and 1,2,3,4,7,8,9-heptachlorodibenzofuran were up to 10 times greater than their WHO-TEF values. Quantitative structure-activity relationship models were used to predict CTFs for untested WHO-TEF compounds, suggesting that the WHO-TEF value for 1,2,3,7,8-pentachlorodibenzofuran could be underestimated by an order of magnitude for both human and rodent models. Our results indicate that the CTF approach provides a powerful tool for condensing data from batteries of screening tests using compounds with similar mechanisms of action, which can be used to improve risk assessment of DLCs